Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study

Ai Ling Shen, Hsiu Li Lin, Yuan Fu Tseng, Hsiu Chen Lin, Chien-Yeh Hsu, Che Yi Chou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
JournalSeizure
Volume29
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Urolithiasis
Cohort Studies
Population
topiramate
Kaplan-Meier Estimate

Keywords

  • Health insurance database
  • Renal stone
  • Topiramate
  • Urolithiasis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Topiramate may not increase risk of urolithiasis : A nationwide population-based cohort study. / Shen, Ai Ling; Lin, Hsiu Li; Tseng, Yuan Fu; Lin, Hsiu Chen; Hsu, Chien-Yeh; Chou, Che Yi.

In: Seizure, Vol. 29, 01.07.2015, p. 86-89.

Research output: Contribution to journalArticle

Shen, Ai Ling ; Lin, Hsiu Li ; Tseng, Yuan Fu ; Lin, Hsiu Chen ; Hsu, Chien-Yeh ; Chou, Che Yi. / Topiramate may not increase risk of urolithiasis : A nationwide population-based cohort study. In: Seizure. 2015 ; Vol. 29. pp. 86-89.
@article{c43c4dbc5bc5489bb3e15c38f0881df6,
title = "Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study",
abstract = "Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9{\%}) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.",
keywords = "Health insurance database, Renal stone, Topiramate, Urolithiasis",
author = "Shen, {Ai Ling} and Lin, {Hsiu Li} and Tseng, {Yuan Fu} and Lin, {Hsiu Chen} and Chien-Yeh Hsu and Chou, {Che Yi}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.seizure.2015.03.009",
language = "English",
volume = "29",
pages = "86--89",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Topiramate may not increase risk of urolithiasis

T2 - A nationwide population-based cohort study

AU - Shen, Ai Ling

AU - Lin, Hsiu Li

AU - Tseng, Yuan Fu

AU - Lin, Hsiu Chen

AU - Hsu, Chien-Yeh

AU - Chou, Che Yi

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

AB - Purpose Topiramate is an effective anti-epileptic drug and can be associated with increased risk for urolithiasis because of its effects on acid-base profile. Evidences that supported an association of topiramate and urolithiasis were limited to case reports or series. We investigated the association of topiramate and urolithiasis in a nationwide population-based cohort study. Methods We analyzed 1377 patients receiving topiramate and 1377 age- and gender-matched control patients (not receiving topiramate) between 1997 and 2008. The risk of urolithiasis was analyzed using Kaplan-Meier analysis, followed by Cox proportional hazard regression. Results Of the 2754 patients, 79 (2.9%) patients developed urolithiasis in two (interquartile range: 1.2-4.2) years. The proportion of patients who developed urolithiasis in the patients receiving topiramate was not different from that of the control patients (p = 0.138, χ2 test). The urolithiasis free survival was not different between the patients receiving topiramate and the control patients (p = 0.168) in Cox proportional hazard regression. The duration and total dosage of topiramate were not associated with risk of urolithiasis in patients receiving topiramate (p = 0.482 and p = 0.751). Conclusion Topiramate may not increase the risk of urolithiasis. The duration and the total dosage of topiramate were not associated with urolithiasis risks.

KW - Health insurance database

KW - Renal stone

KW - Topiramate

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=84930980720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930980720&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2015.03.009

DO - 10.1016/j.seizure.2015.03.009

M3 - Article

C2 - 26076848

AN - SCOPUS:84930980720

VL - 29

SP - 86

EP - 89

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

ER -